Doxorubicin (Dox) is an effective chemotherapeutic for a variety of pediatric malignancies. Unfortunately, Dox administration often results in a cumulative

 

Abstract

Doxorubicin (Dox) is an effective chemotherapeutic for a variety of pediatric malignancies. Unfortunately, Dox administration often results in a cumulative dose-dependent cardiotoxicity that manifests with marked oxidative stress leading to heart failure. Adjunct therapies are needed to mitigate Dox cardiotoxicity and enhance quality-of-life in pediatric cancer patients. Angiotensin-(1-7) [Ang-(1-7)] is an endogenous hormone with cardioprotective properties. This study investigated whether adjunct Ang-(1-7) attenuates cardiotoxicity resulting from exposure to Dox in male and female juvenile rats. Dox significantly reduced body mass and the addition of Ang-(1-7) had no effect. However, adjunct Ang-(1-7) prevented Dox-mediated diastolic dysfunction, including markers of decreased passive filling as measured by reduced early diastole mitral valve flow velocity peak (E) (p<0.05)<0.001)<0.001),<0.05),<0.001)<0.001),<0.05;<0.01)<0.05)

PMID: 32083974 [PubMed - as supplied by publisher]

20:14

Photo

Not included, change data exporting settings to download.

256×256, 6.0 KB

20:14

In reply to this message

pubmed: ctoall&ca or conall

Editor-in-Chief's Top Picks From 2019.

Editor-in-Chief's Top Picks From 2019.

J Am Coll Cardiol. 2020 Feb 25;75(7):776-834

Authors: Fuster V